ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Anti-citrullinated Protein Autoantibodies (ACPAs)"

  • Abstract Number: 1349 • ACR Convergence 2024

    Two Composite Cytokine Scores Predict Flare and Drug-free Remission in Patients with Rheumatoid Arthritis

    Jasmine Sim1, Nandhini Ramamoorthi2, Fiona Rayner3, Abbie Degnan1, Imogen Wilson1, Julie Diboll1, Anna Guttman4, Andrew Melville5, Nisha Rathore2, Stefan Siebert5, Iain McInnes6, Carl Goodyear5, Catharien Hilkens1, Andrew Filer7, Karim Raza7, Christopher Buckley8, Arthur Pratt1, James Wason9, Amy Anderson1, Michael Townsend2, Kenneth Baker1 and John Isaacs1, 1Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 2Genentech, South San Francisco, CA, 3Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, 4Genentech, South San Franscisco, CA, 5School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 6University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, 7Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, 8Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, 9Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom

    Background/Purpose: Recent studies show that half of patients with RA remission can stop conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) therapy to achieve drug-free remission (DFR),…
  • Abstract Number: 0423 • ACR Convergence 2023

    Detection of Citrullinated Proteins Recognized by a Novel Chimeric Antigen Receptor TregTherapy in Both Synovial Fluid and Serum from Patients with Rheumatoid Arthritis

    Sara Charmsaz1, Jeff Tracy1, Elizabeth Whalen1, John Bui1, Anne-Renee van der Vuurst de Vries1, Vivianne Malmström2 and Michelle Blake1, 1Sonoma Biotherapeutics, Seattle, WA, 2Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) is one of the most common autoimmune diseases and despite many therapeutic options, an unmet medical need persists for novel therapies…
  • Abstract Number: 2582 • ACR Convergence 2023

    Expansion of Circulating HLA-DR+ Peripheral Helper T Cells and CXCR5−CD38+ Mature Naïve B Cells in ACPA-positive Individuals At-risk for and with Classified RA

    Hideto Takada1, Kristen Demoruelle1, Kevin Deane1, Shohei Nakamura2, Yasuhiro Katsumata3, Katsunori Ikari2, Jane Buckner4, William H. Robinson5, Jennifer Seifert1, Marie Feser1, LauraKay Moss1, Jill Norri6, Masayoshi Harigai3, Elena Hsieh1, Michael Holer1 and Yuko Okamoto2, 1University of Colorado Anschutz Medical Campus, Aurora, CO, 2Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 3Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, 4Benaroya Research Institute at Virginia Mason, Seattle, WA, 5Stanford University, Palo Alto, CA, 6Colorado School of Public Health, Denver, CO

    Background/Purpose: Production of ACPA following T and B cell interactions is a hallmark of ACPA+ RA. Recently identified peripheral helper T (Tph) cells have B…
  • Abstract Number: 0730 • ACR Convergence 2023

    NF-κB Signaling Is Critically Important for Functional Responses of ACPA-producing B Cell Clones from Patients with Rheumatoid Arthritis

    Giulia Frazzei1, Jan Piet van Hamburg2, Ronald van Vollenhoven2 and Sander Tas3, 1Amsterdam University Medical Center, location AMC, Amsterdam, Netherlands, 2Amsterdam University Medical Centers, Amsterdam, Netherlands, 3Amsterdam UMC, locatie AMC, Utrecht, Netherlands

    Background/Purpose: Anti-citrullinated protein antibodies (ACPA) play a role in rheumatoid arthritis (RA) pathogenesis, and their presence is associated with disease severity. Consequently, detailed analysis of…
  • Abstract Number: 2583 • ACR Convergence 2023

    A Predictive Model for Progression to Clinical Arthritis Based on Lymphocyte Subsets and ACPA in At-risk Individuals with Arthralgia

    Klára Prajzlerová1, Olga Kryštůfková2, Nikola Kaspříková3, Nora Růžičková2, Hana Hulejová1, Petra Hánová1, Jiri Vencovsky4, Ladislav Senolt5 and Maria Filkova2, 1Institute of Rheumatology, Prague, Czech Republic, 2Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 3Faculty of Informatics and Statistics, Prague University of Economics and Business, Prague, Czech Republic, 4Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 5Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic

    Background/Purpose: The positivity of antibodies against citrullinated proteins (ACPA) substantially increases the risk of developing rheumatoid arthritis (RA). The definition of individuals with arthralgia at…
  • Abstract Number: 1139 • ACR Convergence 2023

    From Skin to Bone Lesions: A Pioneer Study Unraveling the Underdiagnosis of SAPHO Syndrome in the Dominican Republic

    Leeany Maletta1, Diana Jimenez2 and Rosanna de Jesus3, 1UNIBE School of Medicine, San Antonio, TX, 2UNIBE School of Medicine, Miami, FL, 3Hospital General Plaza de la Salud, Distrito Nacional, Dominican Republic

    Background/Purpose: SAPHO syndrome is a rare chronic inflammatory condition that affects the skin and osteoarticular structures. Despite being first described over 30 years ago, it…
  • Abstract Number: 1727 • ACR Convergence 2023

    Arthritogenicity of Homocitrullinated Peptides in HLA-DRB1 Transgenic Mice

    Sheri Saunders, Garth Blackler, Patti Kiser, Ewa Cairns and Lillian Barra, Western University, London, ON, Canada

    Background/Purpose: Most rheumatoid arthritis (RA) patients express autoantibodies to post-translationally modified antigens, including citrullinated and homocitrullinated (also known as carbamylated) peptides. Homocitrulline and citrulline are…
  • Abstract Number: 1728 • ACR Convergence 2023

    A Novel Animal Model for Investigating the Effect of HLA-DRB1 on Atherosclerosis

    Garth Blackler, James Akingbasote, Patti Kiser, Christopher Howlett, Ewa Cairns and Lillian Barra, Western University, London, ON, Canada

    Background/Purpose: HLA-DRB1 alleles are associated with various autoimmune and inflammatory conditions, including rheumatoid arthritis, polymyalgia rheumatica, giant cell arteritis, systemic lupus erythematosus, diabetes and atherosclerotic…
  • Abstract Number: 1737 • ACR Convergence 2023

    ACPA, Anti-CarP and AAPA Can Be Detected in Saliva, but Not in Feces of Seropositive Rheumatoid Arthritis Patients – Support for Mucosal Involvement in Specific Locations in RA

    Veerle Derksen1, Klara Martinsson2, René Toes1, Daniel Sjöberg3, Thomas Huizinga1, Alf Kastbom4, Anna Svärd3 and Diane van der Woude1, 1Leiden University Medical Center, Leiden, Netherlands, 2Linköping University, Linköping, Sweden, 3Centre for Clinical Research Dalarna, Uppsala, Sweden, 4Linköping University, Stockholm, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) patients harbor antibodies against several post-translational modifications (AMPA), for example anti-citrullinated protein antibodies (ACPA), anti-carbamylated antibodies (anti-CarP) and anti-acetylated protein antibodies…
  • Abstract Number: 1742 • ACR Convergence 2023

    Sputum Citrullinated Proteins and Sputum Anti-Cit-S100A8/A9 IgG Antibodies Are Increased in Serum Anti-CCP-IgG Positive Individuals Who Developed RA

    Rachna Talluri1, Sudeshna Sen2, Timothy Wilson3, Adam Savage4, Mark Gillespie4, Tom Bumol4, Marie Feser1, Jill Norri5, Michael Holer1, kevin Deane1, Paul Thompson2 and Kristen Demoruelle1, 1University of Colorado Anschutz Medical Campus, Aurora, CO, 2University of Massachusetts Chan Medical School, Worcester, MA, 3Thomas Jefferson University, Philadelphia, PA, 4Allen Institute for Immunology, Seattle, WA, 5Colorado School of Public Health, Denver, CO

    Background/Purpose: The presence of anti-CCP-IgG in the blood identifies individuals who are "at-risk" of developing RA. Our group has reported that in a cohort of…
  • Abstract Number: 1748 • ACR Convergence 2023

    Macrophage Extracellular Traps Require Peptidylarginine Deiminase 2 and 4 and Are a Source of Citrullinated Antigens Bound by Rheumatoid Arthritis Autoantibodies

    S Janna Bashar, Caitlyn Holmes and Miriam Shelef, University of Wisconsin, Madison, WI

    Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) are a hallmark of rheumatoid arthritis, but the sources of citrullinated antigens as well as which peptidylarginine deiminases (PADs) are…
  • Abstract Number: 1751 • ACR Convergence 2023

    Profiling of Anti-PAD IgG and IgA in Patients from the Head-to-head Adalimumab vs Abatacept Rheumatoid Arthritis AMPLE Trial and Matched Healthy Controls

    Namit Kumar1, Xueer Chen2, Mary Ann Aure3, Andy Ishii4, Laura Martinez-Prat5, chelsea Bentow4, Jasmine Saini2, Michael Mahler4 and Laurence Menard2, 1Bristol Myers Squibb, San Diego, CA, 2Bristol Myers Squibb, Princeton, NJ, 3Werfen, Chula Vista, CA, 4Werfen, San Diego, CA, 5Werfen Autoimmunity, Sant Cugat del Vallès, Spain

    Background/Purpose: A hallmark of rheumatoid arthritis (RA) is the presence of anti-citrullinated protein antibodies (ACPA) targeting neoantigens which are generated by a family of enzymes…
  • Abstract Number: 1758 • ACR Convergence 2023

    Identification of Circulating Autoantibodies Associated with ACPA Status in Early Rheumatoid Arthritis

    Lucía Lourido1, Vijay Joshua2, Monika Hansson3, Ronald Sjöberg4, Elisa Pin4, Cristina Ruiz-Romero5, Peter Nilsson4, Lars Klareskog2 and Francisco J. Blanco6, 1Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, Spain, 2Karolinska Institutet, Stockholm, Sweden, 3Division for Rheumatology, Department of Medicine (Solna) Karolinska Institutet, Stockholm, Sweden, 4Department of Protein Science, SciLifelab, KTH Royal Institute of Technology, Stockholm, Sweden, 51) Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España. 4) Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). Av. Monforte de Lemos, 3-5. Pabellón 11,28029, Madrid, Spain, 6Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain

    Background/Purpose: Rheumatoid arthritis (RA) is associated with the presence of autoantibodies being the anti-citrullinated protein antibodies (ACPAs) the hallmark as they are present in almost…
  • Abstract Number: 2124 • ACR Convergence 2023

    Expansion of Atypical B Cells Accompanies Rheumatoid Arthritis-like Immune Dysregulation in ACPA+ At-risk Individuals

    Adam Savage1, Ziyuan He1, Marla Glass1, Julian Reading1, LauraKay Moss2, Marie Feser2, Vlad Tsaltskan3, Katherine Nguyen Nguyen3, Kristen Demoruelle2, kristine Kuhn4, David Boyle3, Cate Speake5, Xiao-Jun Li1, Peter Skene1, Troy Torgerson1, Tom Bumol1, V. Michael Holers6, Jane Buckner7, Gary Firestein8, kevin Deane2 and Mark Gillespie1, 1Allen Institute for Immunology, Seattle, WA, 2University of Colorado Anschutz Medical Campus, Aurora, CO, 3University of California San Diego, La Jolla, CA, 4University of Colorado School of Medicine, Aurora, CO, 5Benaroya Research Institute, Seattle, WA, 6University of Colorado, Denver, CO, 7Benaroya Research Institute at Virginia Mason, Seattle, WA, 8University of California San Diego, San Diego, CA

    Background/Purpose: Seropositive RA is preceded by an at-risk stage characterized by elevated circulating autoantibodies (AAb), including ACPA, in otherwise healthy individuals without clinically-apparent inflammatory arthritis.…
  • Abstract Number: 2144 • ACR Convergence 2023

    Pharmacodynamic Effects of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): Results from the Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2A IRIS-RA Study

    Rohit Panchakshari1, Matthew Loza2, Thomas Huizinga3, Georg Schett4, Keying Ma2, Jocelyn H. Leu2, Sophia G. Liva2, Fowzia Ibrahim5, Bei Zhou6, Qingmin Wang2, Ricardo Rojo Cella2, Chetan S. Karyekar2, Kaiyin Fei2, Carolyn Cuff7 and Sheng Gao2, 1Janssen Research & Development, LLC, La Jolla, CA, 2Janssen Research & Development, LLC, Spring House, PA, 3Leiden University Medical Center, Leiden, Netherlands, 4Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 5Janssen Research & Development, LLC, High Wycombe, United Kingdom, 6Janssen Research & Development, LLC, Chesterbrook, PA, 7Janssen Research & Development, LLC, Cambridge, MA

    Background/Purpose: Nipocalimab is a fully human, immunoglobulin G (IgG) 1 monoclonal antibody that blocks the neonatal crystallizable fragment receptor (FcRn), thereby lowering IgG levels. RA…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology